CTCs detected in a blood sample from a liver cancer patient.

<p>A total of 10 CTCs were detected in this sample; 3 single migratory biophenotypic epithelial/mesenchymal CTCs, 3 single migratory mesenchymal CTCs and a tumor microembolus containing 4 mesenchymal CTCs were observed (epithelial biomarkers are indicated by red fluorescence; mesenchymal biomarkers are indicated by green fluorescence).</p

The three blood samples containing CTM from liver, nasopharyngeal and breast cancers.

<p>The three blood samples containing CTM from liver, nasopharyngeal and breast cancers.</p

EpCAM, CK8/18/19, vimentin and twist expression in HepG2 tumor cells and leukocytes.

<p><b>A</b>: negative control, leukocytes stained for CD45 expression (bright blue fluorescence); <b>B</b>: HepG2 cells stained for EpCAM expression (red fluorescence); <b>C</b>: HepG2 cells stained for CK8 expression(red fluorescence); <b>D</b>: HepG2 cells stained for CK18 expression(red fluorescence); <b>E</b>: HepG2 cells stained for CK19 expression(red fluorescence); <b>F</b>: HepG2 cells stained for vimentin expression (green fluorescence); <b>G:</b> HepG2 cells stained for twist expression(green fluorescence); <b>H:</b> HepG2 cells stained for EpCAM, CK8/18/19, vimentin and twist expression (red/green fluorescence). The cells were analyzed using a 100x oil objective</p

Calibration curve obtained using the optimized CanPatrol CTC enrichment technique in the spiking experiment (n = 8) using HepG2 cells at different dilutions.

<p>Calibration curve obtained using the optimized CanPatrol CTC enrichment technique in the spiking experiment (n = 8) using HepG2 cells at different dilutions.</p

Information and clinical characteristics of the patients.

<p>Information and clinical characteristics of the patients.</p